PRKACA anticorps (C-Term)

N° du produit ABIN5672620

L’anticorps anti-PRKACA Polyclonal produit chez le Lapin a été validé pour WB. Il convient pour la détection de PRKACA dans des échantillons provenant de Humain. }

Aperçu rapide pour PRKACA anticorps (C-Term) (ABIN5672620)

Antigène: PRKACA (Protein Kinase A, alpha (PRKACA))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PRKACA est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-PRKACA anticorps

Épitope: C-Term

Séquence: ATTDWIAIYQ RKVEAPFIPK FKGPGDTSNF DDYEEEEIRV SINEKCGKEF

Purification: Affinity purified

Immunogène: The immunogen is a synthetic peptide directed towards the C terminal region of Human PRKACA

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Détails sur PRKACA

Antigène: PRKACA (Protein Kinase A, alpha (PRKACA))

Autre désignation: PRKACA

Sujet: This gene encodes one of the catalytic subunits of protein kinase A, which exists as a tetrameric holoenzyme with two regulatory subunits and two catalytic subunits, in its inactive form. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. cAMP-dependent phosphorylation of proteins by protein kinase A is important to many cellular processes, including differentiation, proliferation, and apoptosis. Constitutive activation of this gene caused either by somatic mutations, or genomic duplications of regions that include this gene, have been associated with hyperplasias and adenomas of the adrenal cortex and are linked to corticotropin-independent Cushing's syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. Tissue-specific isoforms that differ at the N-terminus have been described, and these isoforms may differ in the post-translational modifications that occur at the N-terminus of some isoforms.

Alias Symbols: PKACA, PPNAD4

Protein Size: 41

Poids moléculaire: 351 kDa

ID gène: 5566

NCBI Accession: NM_001304349, NP_001291278

UniProt: P17612

Pathways: Signalisation NF-kappaB, Signalisation Hedgehog, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Thyroid Hormone Synthesis, Carbohydrate Homeostasis, Myometrial Relaxation and Contraction, M Phase, G-protein mediated Events, Signaling Events mediated by VEGFR1 and VEGFR2, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, Lipid Metabolism, SARS-CoV-2 Protein Interactome, Phosphorylation & l'infection par le SRAS-CoV-2